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A B S T R A C T
Human health and safety depend on reliable measurements in medical diagnosis and on tests that support the
selection and evaluation of therapeutic intervention and newly discovered molecular biomarkers must pass a
rigorous evaluation process if they are to be of beneﬁt to patients. Measurement standardization helps to
maximize data quality and conﬁdence and ultimately improves the reproducibility of published research. Failure
to consider how a given experiment may be standardized can be costly, both ﬁnancially as well as in time and
failure to perform and report pre-clinical research in an appropriately rigorous manner will hinder the devel-
opment of diagnostic methods. Hence standardization is a crucial step in maintaining the integrity of scientiﬁc
studies and is a key feature of robust investigation.
Human health and safety depend on reliable measurements in
medical diagnosis and on tests that support the selection and evaluation
of therapeutic intervention and newly discovered molecular biomarkers
must pass a rigorous evaluation process if they are to be of beneﬁt to
patients. Measurement standardization helps to maximize data quality
and conﬁdence and ultimately improves the reproducibility of pub-
lished research. Failure to consider how a given experiment may be
standardized can be costly, both ﬁnancially as well as in time and
failure to perform and report pre-clinical research in an appropriately
rigorous manner will hinder the development of diagnostic methods.
Hence standardization is a crucial step in maintaining the integrity of
scientiﬁc studies and is a key feature of robust investigation.
Currently, the ﬁeld of molecular biology is lagging behind other
disciplines such as chemistry and physics in terms of the development
of measurement standards that can be used for this purpose [1–4].
Furthermore, research publications applying molecular methods are
often reported in a disparate manner lacking in detail, which confounds
the possibility of reproducing, and ultimately translating a given
ﬁnding to patient care. In recognition of this fact, there have been
several standardization recommendations within the varying ﬁelds of
application (such as microarrays [5], qPCR and digital PCR (dPCR)
[6–8], and sequencing [9,10]). Since the publication of these guidelines
there has been a concerted eﬀort to improve standardization within the
associated literature [11–17]. This includes both consistent laboratory
practices and reporting of methods used as well as appropriate in-
vestigation and validation of relevant reference standard materials
within individual studies.
Our recent review of the literature [18] has shown that the qPCR
data underlying the vast majority of publications reporting use of this
technique are, at the very least, inadequately reported and that the peer
review process allows the publication of incomplete experimental
protocols, yielding results that are diﬃcult to evaluate independently.
An analysis of all colorectal cancer publications that made use of qPCR
between 2006 and 2013 shows that only 3% (n=179) report suﬃcient
experimental detail to allow a reliable assessment of the qPCR data
[19]. That paper also showed that 92% of publications used a single
reference gene, with 13% validating its use and 92% of papers use a
method of analysis that is meaningless unless PCR eﬃciencies are
known, yet 82% do not mention PCR eﬃciency. A more recent analysis
found that 95% of papers (n= 20) used a single reference gene for
normalisation, with only 20% using a single validated reference gene
[20]. Two other surveys found that 100% of papers (n=20) used in-
appropriate analysis and normalisation procedures [21,22]. Other er-
rors, such as incorrect use of controls or even wrong selection of primer
sequences, may not be identiﬁed by the peer review process. Re-
assessment of some of these studies has led to publication retractions
[23–26], encouraged misleading conclusions and wasted both time and
money of funders and researchers following up on these data [18]. Such
errors may be particularly diﬃcult to identify when applying ﬁndings
from one model system to another, for example, ﬁndings from cell line
based studies or animal models being compared and/or applied to
human clinical samples. Discordance in clinical ﬁndings compared to a
model system may be put down to failings in the model system, when in
fact, the study protocols may be at fault.
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Retractions, however, are rare and evidence suggests that this may
be because the original data have not been questioned/re-evaluated
rather than because such mistakes are infrequent [18]. When compre-
hensive reporting practices are not followed, it becomes diﬃcult not
only for such results to be successfully reproduced, but also to de-
termine where the causes of error lie when they arise. Indeed, it may be
the case that a second, conﬂicting study has diﬃculty getting published
at all. Whilst it is accepted that authors of conﬂicting investigations
should collaborate in order to resolve their diﬀerences, this process
would be greatly simpliﬁed if all researchers followed recommended
practices and validated procedures within their own laboratories, as
suggested in this manuscript, and complied with accepted guidelines
(such as MIQE [6]) when reporting data. Of course, it is also possible
that some conﬂicting reports represent the normal biological variation,
but in this instance the signiﬁcance of the diﬀerent ﬁndings will have a
direct impact on what one can conclude from either study, and further
work would be required to understand such discrepancy.
The sources and degree of error should be described and, where
necessary reduced, when validated normalization and best practice
procedures are in place. Our studies employing dPCR have highlighted
discrepancies that cannot always be detected by qPCR, but may still
inﬂuence a measurement result. For example, we have previously de-
monstrated that dPCR is capable of making precise measurements of
synthetic and endogenous RNA molecules in a complex RNA back-
ground [27]. A possible underestimation bias exists for RNA measure-
ments, with RT-dPCR quantiﬁcation being signiﬁcantly lower than that
derived from UV spectrophotometry [27]. RT-dPCR was also shown to
be more precise than reverse transcription (RT)-qPCR, with RT-dPCR
able to highlight the template and assay-speciﬁc biases of diﬀerent one-
step RT-qPCR kits. This demonstrated that cDNA prepared using dif-
ferent RT enzymes, or primed with diﬀerent primers, may result in
diﬀerent yields. For accurate analysis using diﬀerent approaches, the
inherent biases must be understood and factored into a comparison
between diﬀerent PCR approaches or other methods, such as UV
spectrophotometry, capillary electrophoresis or ﬂuorescence-based
measurement.
Diﬀerent extraction methods recover RNA with diﬀering eﬃ-
ciencies, with matrix eﬀects, cell debris and/or the quantity of input
material, such as the number of cells, having an inﬂuence [28–33].
Extraction eﬃciency is particularly relevant when evaluating tran-
scripts of low abundance and so experiment-speciﬁc validation is im-
portant. Furthermore, kit-dependent co-puriﬁed contaminants and ex-
traction buﬀer compounds can aﬀect downstream applications such as
eﬃciency of DNase treatment and RT-qPCR. Both extraction kit/
chemistry and yield determination must be assured in a method spe-
ciﬁc-manner for sample sets to remain equally valid.
When there is maintenance of experimental consistency and an
understanding of sources of bias and error, theoretically any methods
may be expected to generate reproducible results. To assist in this en-
deavour we provide a best practice guide to aid in improving the as-
sessment of sources of error and the translation to reducing experi-
mental error.
Based on the ﬁndings in our previous studies [27,34–36], the au-
thors make the following recommendations for the evaluation of mRNA
levels by RT-qPCR:
General best practice guidelines:
• PCR is arguably the most sensitive molecular method available
today as it has the potential to detect single molecules; consequently
PCR is susceptible to low level contamination. Furthermore, as a
PCR generates billions of copies of the very molecule of interest, this
poses an additional signiﬁcant contamination risk. High copy
number plasmids and synthetic templates should also be considered
a contamination risk on the same level as PCR product.
Consequently, laboratories should comprise areas that separate the
experimental setup (pre-PCR) from subsequent analysis (post-PCR).
Separation of RNA/DNA extraction from PCR reagent preparation
(pre-sample mix) will further reduce contamination risk.
• It is equally important to change lab coats between these areas to
reduce contamination.
• When handling RNA samples at any stage prior to qPCR, it is ad-
visable to employ experimental procedures such as routine treat-
ment of surfaces/racks/pipettes etc. with a solution to remove
RNases (such as RNaseZap, Ambion, or similar alternatives).
• The use of RNase-free plasticware and water is essential.
mRNA measurement by RT-qPCR
• For accurate quantiﬁcation of a given transcript, replication should
be performed at stages that reﬂect the largest source of error, where
this is practical. For example, where an experiment compares the
eﬀect of treatment on a cell culture ideally the experiment should
replicate the culture ﬂasks. Where clinical samples have been pro-
cessed and are available as RNA extracts, it is prevalent to convert
the RNA to cDNA and rely on this sample for the remainder of the
study. However, as the RT step can provide considerable variance,
reliance on a single reverse transcription experiment may lead to
bias generating results that are challenging to reproduce. Working
with and replicating the RNA sample, and therefore the RT, can lead
to a more accurate estimation of the associated error than when just
replicating the qPCR on a single cDNA sample.
• If replication can only be performed at limited stages due to cost/
resources/tissue availability, it should be focussed at earlier steps in
the protocol, i.e. subject/independent experiment replicates should
hold the highest priority.
• Samples may be stored at −80 °C as either lysate or extracted total
RNA. For clinical samples, material should be snap frozen in liquid
nitrogen and stored at −80 °C until processing. Storage at −80 °C
may not be required if a suitable preservative solution, such as
RNAlater or equivalent, is applied.
• For total RNA extraction, diﬀerent methods can yield diﬀerent
amounts of material and matrix components. As such, extraction
methods should be validated on an experimental-speciﬁc basis.
• To reduce the eﬀect of repeated freeze/thaw cycles, total RNA ex-
tracts should have a practical number of aliquots prepared and
stored at −80 °C.
• To protect total RNA from degradation, it is advisable for it to be
diluted in a stabilising agent such as RNA storage solution (Ambion),
or equivalent. This can be a problem with any sample source, but
clinical samples are of special concern because of their complexity
and potential inconsistencies in sample size, collection, storage and
transport can lead to variable quality of RNA templates [34,37,38].
• Total RNA may need to be DNase treated. Where this is the case it is
recommended to assess for DNase eﬃciency, for example by using
Alu PCR [39,40] or equivalent (samples pre and post DNase treat-
ment).
• mRNA should be tested for integrity, using methods such as a 5′-3′
assay, for a highly abundant target [41].
• Extracts should be assessed for co-extracted inhibitors, which can be
tested using the SPUD assay [42,43], or equivalent. However, it is
important to remember that diﬀerent PCR reactions can be diﬀer-
entially aﬀected by inhibitors [44].
• RT may be performed using either one-step or two-step processes.
When measuring low abundance targets, oligo d(T)16 or gene spe-
ciﬁc RT priming is recommended (as opposed to random primers),
based on speciﬁcity for mRNA or speciﬁed targets, respectively.
However, when using diﬃcult samples such as formalin-ﬁxed par-
aﬃn-embedded (FFPE) material, the best approach should be de-
termined on an individual experiment basis.
• Carrier RNA (such as Yeast total RNA) can be added pre-extraction
to aid in the recovery of low abundance targets or targets from
minimal starting material.
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• Carrier RNA can be added to the RT reaction (both one-step and
two-step processes) to aid linear performance of the RTase.
• The validity of the RTase should be tested for each experimental
purpose, particularly when evaluating low abundance targets. When
measuring low abundance mRNA species, one-step RT-qPCR and
RTases lacking RNase H activity should be considered (and vali-
dated).
• If a calibration curve will be used for quantiﬁcation of a target,
reference sample dilutions should be performed at the RNA (not
cDNA) stage (at a minimum n=3 replicates per dilution point).
Furthermore, template type should be maintained where possible,
for example, linearized plasmid should be quantiﬁed using a stan-
dard curve prepared from linearized plasmid.
• External RNA controls, for measurement of a calibration curve or
normalisation purposes, should be spiked into matrix-matched
samples.
• Both positive and negative controls should be utilized throughout
the experimental process.
• qPCR is highly robust and precise and, once optimised, does not
necessarily need to be replicated. However, if a new batch of pri-
mers or probes or a new lot of reagents is introduced, it is advisable
to compare the performance of the assays to ensure comparable
results are achieved.
qPCR Assay design:
• If DNase treatment is performed and validated by Alu PCR, assays do
not necessarily need to be designed to cross an exon–exon boundary,
although this approach is still preferred where possible. DNase
treatment is particularly important when assays cannot be designed
to cross and exon–exon boundary, for example in single exon genes
or pseudogenes. RT negative controls should always be employed as
standard to identify any contaminating DNA.
• All assays should be evaluated for speciﬁcity. Where possible when
performing qPCR, probes such as hydrolysis probes, molecular
beacons and scorpion probes, should be used to ensure additional
speciﬁcity. Where intercalating dyes are used, melt curve analysis
should always be performed to evaluate speciﬁcity.
• An evaluation of PCR eﬃciency, whether by standard curve or any
other of the available methods is essential. Assay eﬃciencies may
also be estimated using ampliﬁcation curve ﬁtting algorithms,
which are dependent on the number of cycles over which there is an
increase in ﬂuorescence, and several such approaches have been
proposed [45–49]. Any such approach must ﬁrst be validated.
Additional considerations:
• For analysis of cell line gene expression, cells of equivalent age
should be evaluated. At a minimum, comparable cell passage, but
ideally cumulative population doubling of cells should be matched
throughout a study.1
• All possible aspects of an experimental set-up should be controlled,
e.g. consistency in sample source/type/processing/storage, reagent
batches, instrument calibration etc.
• Meaningful comparisons can only be made where the same experi-
mental set-up, reagents and methods are used.
• Published data must include all sample and experimental details to
facilitate data reproduction and comparison, either in the main text
or in supplementary ﬁles.
• All sources of variability should be considered and accounted for
before conclusions are made. Especially important is discriminatory
power of the particular experimental process, i.e. the ability of a
particular experimental design to distinguish between diﬀerent
outcomes. If the technical variability of a particular measurement
result is experimentally determined to be 5%, then a biological
diﬀerence of 2% cannot be determined by this experimental set-up.
An estimate of measurement uncertainty should be used to convey
the conﬁdence in a measurement result [50].
These recommendations are summarised in Supplementary Table 1.
Measurement uncertainty has two components: systematic and
random variation [50]. Systematic errors lead to bias in the measure-
ment. These error components are ﬁxed and predictable and may be
inherent to various instruments and methods. Random variation occurs
when making repeated measurements. This is related to precision; a
measure of the degree of agreement between replicate measurement
results obtained for the same sample. Contributing factors are multiple
and include issues of sampling, diﬀerent analysts as well as each stage
of the stepwise protocol necessary for a measurement [50]. Including
an estimate of measurement uncertainty when reporting values allows
comparisons to be made between samples and between data sets, where
appropriate.
Where available, reference materials (including, but not limited to
Certiﬁed Reference Materials) can be used to assist reproducibility be-
tween laboratories, allowing for harmonization of data. dPCR could
assist in the improvement of qPCR through accurate value assignment
of reference materials, and to determine RT enzyme performance [27]
and ensure that the RT enzyme generates the same result as the PCR
enzyme, i.e. counting RNA molecules per cell without the introduction
of bias. This approach may also be applied by reagent manufacturers to
examine extraction procedures. The absolute counting possible with
dPCR methods will allow simple determination of when an RT enzyme
or RNA extraction method is not working eﬃciently and so preventing
biases which cannot always be deﬁned using qPCR. It also oﬀers a
higher level of precision, when such measurements are needed to de-
termine small fold-changes. Such scrutiny of measurement processes
will enable identiﬁcation of biases and so result in improvements to the
experimental protocol. Application of dPCR in this way, as a kind of
process evaluator, would help to keep those processes faithful to the
measurement. It would also allow an improvement of all process steps
and aid harmonisation of protocols and ultimately improve inter-la-
boratory reproducibility. It is important to note that while reproduci-
bility may be improved, this does not necessarily indicate that a result is
accurate.
Important continued eﬀorts include the education and uptake of
standardized laboratory and reporting practices as well as adherence to
recommended guidelines when reviewing manuscripts and grant ap-
plications. When scientists have been doing things a particular way for
years it can be diﬃcult to convince them to change. Seasoned re-
searchers may be resistant to change, especially with funding pressures
and demands to publish. Nevertheless, both compliance with, and dis-
semination of guidelines could be enforced by the requirement of such
standards in manuscripts by publishing journals and funding bodies.
This approach has been successfully employed for animal experiments
(ARRIVE guidelines) [51] and microCT imaging/reporting (ASBMR
guidelines) [52]. Furthermore, capturing training and newly qualiﬁed
young scientists, and ensuring they are schooled in the importance of
such standardization approaches, will go a long way to safeguarding the
integrity of future scientiﬁc endeavor.
The work referenced here further highlights the need for standar-
dization in all aspects of methodology and may be used to guide de-
velopment of studies investigating sources of variability. The employ-
ment of dPCR value assigned calibrant materials (reference samples)
would facilitate greater accuracy for absolute quantiﬁcation by qPCR.
Eﬀorts should focus on internal target standardization approaches,
whether that is using multiple reference genes, expressed repetitive
elements (such as Alu repeats [40]), an alternative approach or a
1 Cumulative population doubling: total number of population doublings of a cell line
since their primary isolation in vitro. An intrinsic measure of the "age" of the particular
culture.
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combination of such methods, and be used to investigate the extent of
variability contributions. It is worth noting that for some applications,
for example measurement challenges requiring high precision and de-
termination of small changes such as transcriptomic biomarkers, as well
as development of new reference materials for biological measurement,
RT-dPCR may be more appropriate than RT-qPCR.
The accomplishment of such standardization measures may be
problematic in practice, particularly in clinical laboratories. However,
for RT-qPCR data to be robust it is necessary to implement a standar-
dized approach, to be aware of (and deﬁne) limitations and to include
appropriate calibrators or reference materials, which will allow ap-
propriate data normalisation.
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